Skip to main content

Positron Emission Tomography (PET) Market to Expand with Advancements in Cancer Imaging by 2030

 



The global Positron Emission Tomography (PET) market is set to witness a growth rate of 5% in the next 5 years. Growing prevalence of chronic diseases; technological advancements in radiopharmaceuticals and PET systems; increasing demand for early and precise diagnosis; rising applications in oncology and neurology; and increasing investments, funds, and grants by public-private organizations are some of the key factors driving the PET market.

PET is a sophisticated imaging technique used primarily in medical diagnostics. It employs a radioactive substance known as a radiotracer, which is injected into the patient's bloodstream. As the radiotracer accumulates in tissues, it emits positrons that are detected by a PET scanner, creating detailed images of metabolic activity within the body. This allows healthcare providers to identify abnormalities such as tumors, assess heart function, and evaluate brain disorders. PET scans are particularly valuable for detecting diseases at early stages, often before they are visible through other imaging methods like CT or MRI scans.

🔗 Want deeper insights? Download the sample report:

https://meditechinsights.com/global-positron-emission-tomography-pet-market/request-sample/

Technological advancements in radiopharmaceuticals and PET systems to propel market demand

Technological advancements in radiopharmaceuticals are significantly driving the growth of the PET market. The development of novel radiotracers, such as Gallium-68 and Fluorine-18-labeled compounds, has expanded PET applications beyond oncology to neurology, cardiology, and infectious diseases. These advancements enhance diagnostic accuracy by targeting specific biomarkers, enabling early and precise disease detection. Improved radiotracer production technologies, such as automated synthesis systems and compact cyclotrons, ensure a steady supply of high-quality radiopharmaceuticals, even in remote areas. This progress supports the growing demand for PET imaging in personalized medicine, further boosting its adoption across healthcare systems globally.

Rising applications in oncology and neurology are driving the market growth

Rising applications in oncology and neurology are key drivers of the PET market. In oncology, PET is invaluable for detecting, staging, and monitoring various cancers, offering precise insights into tumor activity and treatment effectiveness. Radiotracers like FDG enable early cancer detection and help tailor therapies. In neurology, PET aids in diagnosing neurodegenerative disorders such as Alzheimer’s and Parkinson’s by visualizing brain metabolism and amyloid plaques. It also helps assess epilepsy and monitor responses to neurological treatments. These expanding applications highlight PET’s role in improving clinical outcomes, driving its adoption in advanced diagnostic and therapeutic practices.

Competitive Landscape Analysis

The global positron emission tomography (PET) market is marked by the presence of established and emerging market players such as GE HealthCare, Koninklijke Philips N.V., Siemens Healthineers, Shimadzu Corporation, Canon Medical Systems Corporation, Neusoft Medical Systems Co., Ltd., Oncovision, Positron, MinFound Medical Systems Co., Ltd, and CMR Naviscan; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Gain a competitive edge-request a sample report now! 

https://meditechinsights.com/global-positron-emission-tomography-pet-market/request-sample/

Market Segmentation

This report by Medi-Tech Insights provides the size of the global positron emission tomography (PET) market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, end user.

  • Market Size & Forecast (2023-2030), By Product, USD Million
    • Standalone PET Systems
    • PET/CT Systems
      • Low-Slice Scanners
      • Medium-Slice Scanners
      • High-Slice Scanners
    • PET/MRI Systems
  • Market Size & Forecast (2023-2030), By Application, USD Million
    • Oncology
    • Neurology
    • Cardiology
    • Infectious Diseases
    • Others
  • Market Size & Forecast (2023-2030), By End User, USD Million
    • Hospitals
    • Diagnostic Imaging Centers
    • Ambulatory Surgical Centers (ASCs)
    • Others
  • Market Size & Forecast (2023-2030), By Region, USD Million
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Rest of Asia Pacific
    • Latin America
    • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
 
info@meditechinsights.com 

Comments

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...

Global Cell Isolation Market projected to grow at 11% CAGR with R&D in oncology therapies by 2030

  The global cell isolation market is projected to grow at a CAGR of 11% from 2025 to 2030,  driven by rising investments in cell-based research, increasing adoption of cell therapies, and growing demand for biopharmaceutical production. Growth is further supported by technological advancements in isolation methods, increasing R&D activities in regenerative medicine, and expanding clinical applications for isolated cells.  Cell isolation is a fundamental process in life sciences and clinical research, involving the separation of specific cell types from complex biological samples. The market is expanding due to growing applications in stem cell research, cancer biology, immunology, and personalized medicine. Additionally, improvements in magnetic-activated cell sorting (MACS), fluorescence-activated cell sorting (FACS), and microfluidic technologies are making cell isolation more efficient, reproducible, and scalable. To request a free sample copy of this report,...

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...